Meridian Bioscience

The company said it broadened the scope of its life science products to include COVID-19 reagents used by manufacturers to develop rapid antigen tests.

Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.

Of the 28 companies in the index, 21 firms saw their stock prices increase, while seven firms' share price decreased. 

Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.

Increased revenues in the company's life science segment due to demand for its COVID-19-related products drove Meridian's overall growth.

Of the 28 companies in the index, 27 firms saw their stock prices increase, while one firm's share price decreased slightly.

News items for the in vitro diagnostics industry for the week of April 27, 2020. 

BioMérieux's BioFire received clearance for its Blood Culture Identification 2 Panel for the identification of nucleic acids associated with bacteria and yeast.

The company said the revenue increase is driven primarily by growth in the life science segment due to high demand for SARS-CoV-2 molecular products.

The analyzer and assay use immunofluorescent technology to detect H. pylori antigens in human stool and helps eliminate subjectivity.